Pharmacology Of Cefotetan

Indication	For prophylaxis and treatment of bacterial infections.
Pharmacodynamics	Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.
Mechanism of action	The bactericidal action of cefotetan results from inhibition of cell wall synthesis by binding and inhibiting the bacterial penicillin binding proteins which help in the cell wall biosynthesis.
Absorption	Not Available
Volume of distribution	10.4 L [elderly patients (greater than 65 years) with normal renal function] 10.3 L [healthy volunteers (aged 25 to 28 years)]
Protein binding	Cefotetan is 88% plasma protein bound.
Metabolism	No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug.
Route of elimination	No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. In normal patients, from 51% to 81% of an administered dose of Cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations.
Half life	In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged
Clearance	1.8 +/- 0.1 L/h [elderly patients with normal renal function (.65 years)] 1.8 +/- 0.3 L/h [healthy volunteers (aged 25 to 28 years)]
Toxicity	Not Available